FAQ and Inquiries

FAQ

For Companies

What are the features of ARCAD Asia?

ARCAD Asia makes it possible to perform analyses that are impossible with a single clinical study by operating a system to share and utilize data (data sharing) on clinical trials and studies carried out individually by pharmaceutical companies and researchers, and is expected to help produce a broad range of research outcomes, including regulatory science.

What are the advantages of data sharing?

Data sharing will integrate data across Asia into big data, which can promote investigations on drug development, especially on streamlining clinical trials, thereby contributing to drug development in Asia. For more details, please contact the ARCAD Asia office.

Will data shared by ARCAD Asia be open to the public?

No, ARCAD Asia's data will never be open to the public. Only results will be provided in such a way that they can help promote the efficiency of drug development (early approval) and the improvement of healthcare.

For Patients and the General Public

Is ARCAD Asia's Data Management safe?

Yes, it is. ARCAD Asia's data is stored in the ARCAD Asia data center and can only be handled by a limited number of internal staff members.

In what way does ARCAD Asia help?

ARCAD Asia helps gain new insights by analyzing its data on small groups of patients, such as advanced age patients, in one batch. In addition, if a drug meets some criteria, such as being already in wide use overseas, an application for approval can be submitted without conducting a new study. As such, ARCAD Asia is expected to expedite drug approval in Japan.

May I participate in ARCAD Asia?

ARCAD Asia is an initiative to reuse data on patients that have already participated in clinical studies and trials so as to gain new insights. Since we do not conduct new studies, we do not seek new patients.

Inquiries

ARCAD Asia Office, National Cancer Center Hospital East

Email: arcadasia_office●east.ncc.go.jp(Please replace ● with @)